> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# QuidelOrtho Gets Lenders To Allow 5.50x Leverage Through 2028 While Cash Burn Continues
- URL: https://www.bullished.co/quidelortho-gets-lenders-to-allow-5-50x-leverage-through-2028-while-cash-burn-continues-c4ef8551/
- Published: 2026-11-04T11:06:15.000Z
- Updated: 2026-11-04T11:06:15.000Z
- Description: A September credit amendment loosens debt tests through September 2029 as nine-month operating cash flow stays negative at $124.0 million.
- Author: Matteo Parrino
- Tags: SEC Filings, QDEL, Industry: Healthcare

[QuidelOrtho](https://www.bullished.co/tag/qdel/), which makes diagnostic tests and the instruments that run them, rewrote its borrowing limits on September 23, letting its debt load reach [5.50 times](https://www.sec.gov/Archives/edgar/data/0001906324/000190632426000042/qdel-20260927.htm?ref=bullished.co) a leverage measure through July 2, 2028, its 10-Q filed Wednesday shows. The prior quarter's filing described a [4.50 limit](https://www.sec.gov/Archives/edgar/data/0001906324/000190632426000033/qdel-20260628.htm?ref=bullished.co), and the company burned cash over the first nine months.

## Looser tests, bigger fee

The amendment to the company's credit agreement with Bank of America and other lenders also cuts the minimum interest coverage ratio to 2.25 from 3.00 through July 2, 2028\. Both tests tighten in steps across what the filing calls the Covenant Relief Period, which runs through the quarter ending September 30, 2029\. By then the leverage cap steps down to 4.25 and the coverage floor returns to 3.00.

QuidelOrtho paid $4.3 million in lender fees: $2.7 million on Term Loan A and $1.6 million on the revolving credit facility. It also expensed $0.5 million of third-party costs. Pricing on the Term Loan A and the revolver now floats on a grid tied to leverage, from 1.75% to 3.00% over the Term SOFR benchmark rate, and the company pays a commitment fee of 0.20% to 0.40% on unused credit. Interest on Term Loan B is unchanged. The company said it was in compliance with its financial covenants at September 27.

## Borrowing up, cash burn deeper

The reset came as debt rose. The revolver balance stood at $315.0 million, up from $80.0 million at the end of 2025, and the current portion of borrowings reached $424.4 million from $178.3 million. Interest expense for the nine months was $161.2 million, against $126.6 million a year earlier.

Operating activities used $124.0 million in cash over nine months, compared with $26.7 million used a year earlier. Inventories rose to $642.7 million from $577.6 million at year-end, and cash ended at $166.4 million. Nine-month revenue fell 7% to $1,869.6 million, which the company tied to weaker U.S. flu and COVID sales, the end of its Grifols joint business and China market changes. The company also owes Grifols a $65.0 million charge over three years for ending the venture, of which it paid $25.0 million this year.

## New restructuring and a test expiry

The company launched a cost program built around two units, Core Diagnostics and Point of Care Diagnostics. It expects more than $80 million in annual savings in 2027 and about $30 million to $35 million of one-time charges in the fourth quarter of 2026.

Respiratory revenue may also become lumpier. The federal declaration backing emergency authorizations for COVID tests ends December 26, 2026, which affects the company's SOFIA Combo flu-and-COVID test. It can keep selling after that date only if the FDA accepts a 510(k) submission before then, and some customers may stock up in advance.

The covenant cushion is built to shrink: by the quarter ending September 30, 2029, the leverage cap is back to 4.25 times and the interest coverage floor to 3.00.

### Sources

- [10-Q Filing — QuidelOrtho (QDEL)](https://www.sec.gov/Archives/edgar/data/0001906324/000190632426000042/qdel-20260927.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — QuidelOrtho (QDEL), Q2 FY2026 filed 2026-08-07 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001906324/000190632426000033/qdel-20260628.htm?ref=bullished.co) — SEC EDGAR
- [8-K Filing — QuidelOrtho, filed 2026-11-03 (Items 2.02, 5.02, 9.01)](https://www.sec.gov/Archives/edgar/data/0001906324/000190632426000040/qdel-20261103.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, qdel9272026ex991earningsre.htm) — QuidelOrtho, filed 2026-11-03](https://www.sec.gov/Archives/edgar/data/0001906324/000190632426000040/qdel9272026ex991earningsre.htm?ref=bullished.co) — SEC EDGAR

### More on QuidelOrtho

- [QuidelOrtho Launches Restructuring Targeting Over $80 Million In 2027 Savings, As CEO Weighs 'Every Option' On Debt](https://www.bullished.co/quidelortho-launches-restructuring-targeting-over-80-million-in-2027-savings-as-ceo-weighs-48deb372/)
- [QuidelOrtho Revenue Falls 12% To $619 Million, Trims Outlook And Starts Restructuring](https://www.bullished.co/quidelortho-revenue-falls-12-to-619-million-trims-outlook-and-starts-restructuring-b6232a59/)

[All QuidelOrtho (QDEL) coverage →](https://www.bullished.co/tag/qdel/)